BioNTech raised $270M in a series A venture round at the start of 2018 as it pursues an ambition to create a fully integrated biopharmaceutical company. During BIO-Europe Spring 2018, BioNTech COO Sean Marett told Scrip how the funds will be invested.
BIO-Europe Spring Interviews